Inhibitor Therapeutics (INTI) Share-based Compensation (2013 - 2025)
Inhibitor Therapeutics' (INTI) quarterly Share-based Compensation came in at -$15000.0 in Q4 2025, up 28.57% YoY from -$11666.7 in Q4 2024, and down 278.89% on a QoQ basis from $8385.0 in Q2 2025.
Inhibitor Therapeutics (INTI) Share-based Compensation (2013 - 2025) Analysis & Trends
Inhibitor Therapeutics (INTI) has 12 years of Share-based Compensation data on file, last reported at -$15000.0 in Q4 2025.
- Quarterly Share-based Compensation rose 28.57% year-over-year to -$15000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$27615.0 (down 1478.0% YoY) and the FY2025 annual result came in at $8385.0, down 56.44% from the prior year.
- Share-based Compensation eased to -$15000.0 in Q4 2025, from $8385.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $62832.0 in Q2 2021 to a low of -$62832.0 in Q3 2021.
- A 4-year average of $3462.1 and a median of $1534.0 in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2021 — Share-based Compensation sank 225.78% — and 2025, when it soared 622.84%.
- Tracing INTI's Share-based Compensation over 4 years: stood at -$62832.0 in 2021, then soared by 102.44% to $1534.0 in 2023, then tumbled by 1468.97% to -$21000.0 in 2024, then gained by 28.57% to -$15000.0 in 2025.
- The last three Share-based Compensation figures came in at -$15000.0 (Q4 2025), $8385.0 (Q2 2025), and -$21000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15,000.00 |
| Dec 31, 2025 | -15,000.00 |
| Jun 30, 2025 | 8,385.00 |
| Jun 30, 2025 | 8,385.00 |
| Dec 31, 2024 | -21,000.00 |
| Dec 31, 2024 | -21,000.00 |
| Jun 30, 2024 | 1,160.00 |
| Jun 30, 2024 | 1,160.00 |
| Mar 31, 2024 | 18,090.00 |
| Mar 31, 2024 | 18,090.00 |
| Sep 30, 2023 | 1,534.00 |
| Sep 30, 2023 | 1,534.00 |
| Sep 30, 2021 | -62,832.00 |
| Sep 30, 2021 | -62,832.00 |
| Jun 30, 2021 | 62,832.00 |
| Jun 30, 2021 | 62,832.00 |
| Mar 31, 2021 | 37,990.00 |
| Mar 31, 2021 | 37,990.00 |
| Dec 31, 2020 | 119,336.00 |
| Dec 31, 2020 | 119,336.00 |